fbpx

News

Lundbeckfonden Ventures News

Cambridge, UK and Indianapolis, US –  12 August 2019: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”, the “Group”), (EURONEXT: ACPH), a pharmaceutical company developing and commercialising hospital products for US and international markets, will issue its interim results for the six-month period ended 30 June 2019 on Thursday 5 September 2019. A conference call will...
Lund, Sweden, 18:00 CET 31 July 2019 –  During July, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to the exercise of warrants. As of 31 July 2019, the number of shares in BONESUPPORT HOLDING AB (publ) amounts to 52,351,417 shares, of which 51,846,417 are ordinary shares with one...
Lund, Sweden, 08.00 am CET, 25 July 2019 – BONESUPPORT™, listed on Nasdaq Stockholm – BONESUPPORT HOLDING AB (publ) – listed on Nasdaq Stockholm – an emerging leader in orthobiologics for the management of bone voids, today publish the financial report for thean emerging leader in orthobiologics for the management of bone injuries, today publishes...
Veloxis Pharmaceuticals A/S (OMX: VELO) announced today that it is raising its Outlook for 2019.  This improvement is primarily driven by better than expected uptake of de novo use of Envarsus XR® (tacrolimus extended-release tablets) following the launch of the new indication in January of this year.  In addition to the better than expected de...
Lund, Sweden, 08.00 am CET, 18 July 2019 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids will publish its Q2 2019 Interim Report on 25 July 2019 at 08:00 am CET. The Company will hold a conference call and an online presentation on the same day at 13.00 CET. The...
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US –  18 July 2019: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”, the “Group”), (EURONEXT: ACPH), a pharmaceutical company developing and commercialising hospital products for US and international markets, announces that its...
Type C Meeting confirmed that FDA does not believe additional clinical safety, efficacy, or pharmacology studies will be required to support NDA resubmission and review FDA confirmed that the resubmission would be under the current NDA Company accelerates timeline and now expects resubmission of FUROSCIX NDA with the FDA by mid-year 2020 BURLINGTON, Mass., July...
Cambridge, UK and Indianapolis, US – 12 July 2019: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH) welcomes an editorial published in the leading peer-reviewed journal Anesthesia & Analgesia, accompanying the print publication of results from its positive Phase 3 clinical trial of BARHEMSYS® (intravenous amisulpride) as treatment of post-operative nausea & vomiting...
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 8 July 2019: Acacia Pharma Group plc (“Acacia Pharma” or “the Company”), a pharmaceutical company developing and commercialising hospital products for US and international markets, announces receipt of the official...
1 2 3 58

Lundbeckfonden Ventures

News

Acacia Pharma Group PLC – Acacia Pharma Group plc: Notice of Interim Results
12. August 2019
Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)
31. July 2019
BONESUPPORT HOLDING AB (publ) – Publishes Q2 2019 Interim report
25. July 2019